Quick Listen: Scrip’s Five Must-Know Things
Coronavirus Vaccines, Psoriasis, China Oncology And More
Executive Summary
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major biopharmaceutical developments in the business week ended 24 July 2020.
Progress with coronavirus vaccines, a new contender in psoriasis, oncology strategy in China and a new trial in spinal muscular atrophy are on the table this week.
Stories mentioned in this episode:
(Also see "New Pfizer/BioNTech COVID-19 Vaccine Data Confirm Prior Results, Show T-Cell Boost" - Scrip, 20 Jul, 2020.)
(Also see "Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal" - Scrip, 20 Jul, 2020.)
(Also see "Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis" - Scrip, 17 Jul, 2020.)
(Also see "Roche Rides Partnership, Digital Wave To Widen China Oncology Drug Access" - Scrip, 20 Jul, 2020.)
(Also see "One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma" - Scrip, 21 Jul, 2020.)